The Trump administration has opened a new front in its ongoing campaign against transgender healthcare, filing a lawsuit against the World Professional Association for Transgender Health (WPATH), the organization whose Standards of Care have guided treatment for transgender patients around the world for decades.
On June 17, the U.S. Federal Trade Commission (FTC), joined by the attorneys general of Texas, Iowa, Nebraska, and Alaska, filed suit against WPATH in federal court. The complaint accuses the organization of making misleading claims about the benefits and risks of gender-affirming medical care for transgender youth. The lawsuit represents one of the most significant federal actions yet targeting a major medical organization involved in transgender healthcare.
According to the FTC, WPATH allegedly overstated evidence connecting gender-affirming care with improved mental health outcomes and reduced suicide risk among transgender adolescents. The agency also claims the organization failed to adequately disclose potential risks associated with treatments such as puberty blockers and hormone therapy.
WPATH has long maintained that its Standards of Care are evidence-based clinical guidelines developed through decades of research and expert review. The organization has repeatedly stated that treatment decisions should be individualized and made collaboratively between patients, families, and qualified healthcare providers.
The lawsuit comes after months of escalating conflict between WPATH and the FTC. Earlier this year, WPATH sued the commission over a Civil Investigative Demand seeking internal documents and communications related to its standards of care. The organization argued the investigation was politically motivated and designed to intimidate medical professionals who support transgender healthcare. A federal judge later granted preliminary relief limiting aspects of the FTC’s investigative efforts.
Critics of the new lawsuit argue that the FTC is stepping far outside its traditional consumer protection role. Unlike agencies that regulate medical practice, the FTC typically focuses on deceptive advertising and unfair business practices. Legal experts and LGBTQ+ advocates have questioned whether the commission should be determining the validity of medical guidelines established by professional healthcare organizations.
The case also arrives amid a broader effort by the Trump administration to restrict access to gender-affirming care nationwide. Federal investigations have targeted multiple medical organizations, while healthcare providers in some states have scaled back services due to legal uncertainty and political pressure.
For transgender people and their families, the lawsuit raises concerns that political battles are increasingly being fought through healthcare systems and professional medical organizations. While the legal challenge focuses on WPATH, its outcome could have far-reaching consequences for providers, insurers, and patients who rely on established standards of care to access medically necessary treatment.
As the case moves forward, it is likely to become another major test of whether federal agencies can use consumer protection laws to challenge mainstream medical guidance on transgender healthcare.
